Subtraction 6

Agitation is
an early sign
of Alzheimer’s

Join the S-CitAD study today

Are you a clinician? Learn more
What is Agitation?

Agitation. You’ve felt it before. If you’re lucky, it’s fleeting and rare. But for thousands of people, persistent, inexplicable agitation can be an early and distressing sign of Alzheimer’s disease. It can appear in many forms and is not always severe:

Recognizing these symptoms and seeking treatment early is critical. A new study led by Johns Hopkins Medicine and several clinical research partners across the United States and Canada are testing a novel therapeutic approach to treat agitation in patients with Alzheimer’s disease.

Constantly moving around or pacing uncontrollably
Mood swings—going from calm to angry for no reason
Becoming fixated on specific details
Feeling overwhelmed by a word that no longer makes sense

Subtraction 9
What is S-CitAD?

The Escitalopram for Agitation in Alzheimer’s Disease (S-CitAD) study is being conducted to determine if a study drug given as a pill can safely and effectively reduce the symptoms of agitation and aggression in people with Alzheimer’s disease.
This study is funded by the people of America through a grant from the National Institute on Aging. It has not received any funding from a pharmaceutical company.

Do you or a loved one qualify?

Have an Alzheimer's diagnosise
Frequent symptoms of agitation or aggression
Caregiver or family member with the time to spend several hours per week supervising care and accompanying the participant to study visits.
Available for 3 months of follow-up

Study Criteria
Study Site Locations

To contact one of our study sites, click on the map or send an email to

Subtraction 8
S-CitAD Map
Get Started

If you (or someone you know) have dementia and struggle with agitation, irritability, or similar behaviors, you might be eligible to participate.

© 2017-2023 The CitAD Research Group